Extramedullary Disease in AML Does Not Affect HCT Outcomes

Researchers analyzing outcomes of 9,797 allogeneic transplants in patients with AML - including 814 patients with extramedullary disease (EMD) - have found that EMD does not affect transplant outcomes. Multivariate analyses of transplant outcomes reported to CIBMTR (Center for International Blood and Marrow Transplant Research) found that pre-transplant presence of EMD had no significant effect on overall survival (HR: 1.00; 95% CI: 0.91-1.09), leukemia-free survival (HR: 0.98; 95% CI: 0.89-1.09), transplant-related mortality (RR: 0.92; 95% CI: 0.80-1.16; p=0.23), or relapse (RR: 1.03; 95% CI: 0.92-1.16; p=0.62). The researchers concluded that “the presence of EMD in AML does not affect transplant outcomes and should not be viewed as an independent adverse prognostic feature.”

Goyal SD, et al. Bone Marrow Transplant

Related Resources